The short version
Tirzepatide acts on signals called GIP and GLP-1. The selected study below compares blood-sugar control in people with type 2 diabetes; the Mounjaro label provides a separate product-specific reference.
Prescription status is product-specific. A recognized ingredient name does not make every preparation equivalent.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Tirzepatide
- Compound name · The ingredient name.
- Mounjaro
- Brand name · A specific prescription product; the brand does not apply to every preparation.
- GLP-2 / GLP2 / GLP-2 TZ
- Ambiguous seller shorthand · Used for tirzepatide in some listings. GLP-2 also names a different biological hormone; context is essential. Do not treat this label alone as molecular identification.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Does the evidence match the preparation being discussed?
Check the exact product or substance, route, population and outcome. Ask which findings apply to your question, rather than assuming every product with the same ingredient name is equivalent.
Question to discuss · DailyMed · Mounjaro prescribing information ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
Clinical trial findings are described in the product label. Findings for a labeled medicine do not establish the quality or safety of an unrelated preparation.
SURPASS-2 · type 2 diabetes (2021)
Summary based on: Published abstract
- Study design
- Randomized, open-label, phase 3 trial; 40 weeks.
- Who was studied
- 1,879 patients with type 2 diabetes.
- Route and preparation
- Subcutaneous injections of the compared study drugs.
- What was compared
- Weekly injected tirzepatide at three study doses versus injected semaglutide 1 mg weekly. Participants knew which drug they received; this was not a comparison of every available dose or product.
- What researchers found
- HbA1c, a measure of longer-term blood sugar, fell by an average of 2.01–2.30 percentage points across the tirzepatide groups, compared with 1.86 points in the semaglutide group.
- Adverse events and stopping treatment
- Gastrointestinal events were common. Serious adverse events were reported in 5–7% of tirzepatide participants across groups, versus 3% with semaglutide; reporting an event does not establish its cause.
- What this leaves unanswered
- The main comparison concerned blood-sugar control in type 2 diabetes. It does not establish which treatment is best for someone without diabetes, or compare all weight-management regimens.
- Funding context
- The trial was funded by Eli Lilly.
Research terms in everyday language ↗
Selected study summary based on the linked abstract; full-text appraisal, adverse-event detail, funding review, and a broader literature search are still pending.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- GIP + GLP-1 receptor agonist
- Name variations
- Names you may see and important distinctions
- Source type
- U.S. prescribing information
- Reference jurisdiction
- United States
A receptor is a structure that receives a chemical signal. An agonist activates a receptor. The mechanism section of the linked label explains the relevant pathway in greater detail.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 7 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗